美股异动 |Fusion Pharmaceuticals 盘前飙涨 94% 阿斯利康拟溢价近一倍收购

YiCai
2024.03.19 08:22
临床阶段生物制药公司 Fusion Pharmaceuticals(FUSN.US) 盘前飙涨 94%，报 20.65 美元。消息上，阿斯利康周二表示，将以约 20 亿美元现金收购 Fusion Pharmaceuticals，以扩大其肿瘤产品组合。阿斯利康将以每股 21 美元的价格收购 Fusion，较这家美国上市公司周一的收盘价溢价逾 97%。阿斯利康还将支付每股 3 美元的不可转让或有价值权，使合并交易价值达到
Source: YiCai The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.